FLUCELVAX QUADRIVALENT Rx
Generic Name and Formulations:
Quadrivalent, inactivated, "subunit" influenza vaccine (virus types A and B); contains a total of 60mcg of hemagglutinin per 0.5mL dose; formulation changes annually; susp for IM inj; antibiotic-free.
Indications for FLUCELVAX QUADRIVALENT:
Adults and Children:
<4yrs: not established. Each dose is 0.5mL by IM inj once in the deltoid. 4–8yrs: 1 or 2 doses at least 4wks apart (depending on vaccination history as per annual ACIP recommendation). ≥9yrs: 1 dose.
Use current formulation only. Have appropriate medical treatment and supervision readily available. Guillain-Barre syndrome within 6 weeks of previous flu vaccine. Immunosuppressed. Pregnancy (Cat.B). Nursing mothers.
Concomitant vaccines: insufficient data (see full labeling). Immunosuppressants: may get suboptimal response.
Local reactions (eg, pain, erythema, induration), headache, fatigue, myalgia; syncope.
Single-dose prefilled syringe 0.5mL (preservative-free)—10 (without needles); Multi-dose vial 5mL (contains thimerosal)—1
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma